I'm not some huge fan of dilution, but it's to be expected in this situation. Same with those shares converted from debt. It's unfortunate for stockholders, but a very big plus for the company to finance their operations and continue on.
I think the $3.3 million at 0.30 per share says two things:
1) The days of 0.08-0.15 pps are gone.
2) Someone with a lot of money has a ton of confidence in Aethlon. Notice the press release made it a point to indicate this investment was made by a single investor with interest in institutional biotech stocks.
Lots happening day after day. Exciting time to be a shareholder (especially for all of us longs that have been holding for years) that's for sure.